Sharing this US Second Circuit court decision that was first reported 12/4/12. I'm sharing this herein at Newsvine because I'm surprised no one else seemed to have heard about it or picked up on it.
In essence, the court ruled that it is okay to off-label market drugs, that off-label marketing of drugs is ( in their view) an expression of First Amendment rights.
Although I am not a physician, the idea that a drug designed and clinically-tested and Food-and-Drug Administration-approved for one condition (or a closely-defined group of conditions) could now be marketed for other conditions without subsequent re-testing and approval.
Help me here. This court decision sounds ill-advised and dangerous. And product liability class-action suit bidding legal teams probably cannot wait to pounce on what could be a gold-mine of just awful outcomes, when patients are negatively-impacted by mis-diagnosed medications.
We need to be careful here.